All In Biotech

Drug Trial Radar · NCT06182774

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

570

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Jan 31, 2032

Study completion Jul 31, 2032

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Canadian Institutes of Health Research (CIHR); Myeloma Canada
First posted
Dec 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Dose determined at enrollment

  • LenalidomideDrug

    Dose determined at enrollment

  • DexamethasoneDrug

    Dose determined at enrollment

  • IsatuximabDrug

    Dose determined at enrollment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: 9.1 years

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • BCCA - Kelowna

    Kelowna, British Columbia, Canada · Recruiting

  • BCCA - Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada · Recruiting

  • The Moncton Hospital

    Moncton, New Brunswick, Canada · Recruiting

  • Regional Health Authority B, Zone 2

    Saint John, New Brunswick, Canada · Recruiting

  • Dr. H. Bliss Murphy Cancer Centre

    St. John's, Newfoundland and Labrador, Canada · Recruiting

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, Canada · Recruiting

  • William Osler Health System

    Brampton, Ontario, Canada · Recruiting

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada · Recruiting

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada · Recruiting

  • Waterloo Regional Health Network (WRHN)

    Kitchener, Ontario, Canada · Recruiting

  • London Health Sciences Centre Research Inc.

    London, Ontario, Canada · Recruiting

  • Trillium Health Partners - Credit Valley Hospital

    Mississauga, Ontario, Canada · Recruiting

  • Stronach Regional Health Centre at Southlake

    Newmarket, Ontario, Canada · Recruiting

  • Oakville Trafalgar Memorial Hospital

    Oakville, Ontario, Canada · Recruiting

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada · Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • Algoma District Cancer Program

    Sault Ste. Marie, Ontario, Canada · Recruiting

  • Niagara Health System

    St. Catharines, Ontario, Canada · Recruiting

  • Thunder Bay Regional Health Sciences Centre/

    Thunder Bay, Ontario, Canada · Recruiting

  • St. Michael's Hospital

    Toronto, Ontario, Canada · Recruiting

  • St. Joseph's Health Centre

    Toronto, Ontario, Canada · Recruiting

  • Windsor Regional Cancer Centre

    Windsor, Ontario, Canada · Recruiting

  • CIUSSS de l'Est-de-I'lle-de-Montreal

    Montreal, Quebec, Canada · Recruiting

  • The Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • St. Mary's Hospital

    Montreal, Quebec, Canada · Recruiting

  • The Research Institute of the McGill University

    Montreal, Quebec, Canada · Recruiting

  • CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)

    Québec, Quebec, Canada · Recruiting

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada · Recruiting

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.